Method for treatment of diseases

• US 9,233,113 B2
• Filed: 06/22/2010
• Issued: 01/12/2016
• Est. Priority Date: 06/22/2009
• Status: Expired due to Fees

• Current Assignee: Ampio Pharmaceuticals, Inc.
• Original Assignee: Ampio Pharmaceuticals, Inc.
• Inventors: Bar-Or, David
• Primary Examiner(s): SZNAIDMAN, MARCOS L
• Application Number:
  US12/820,398
• Publication Number:
  US 20100324005A1
• Time in Patent Office: 2,030 Days
• Field of Search: 514/183, 514/176
• US Class Current: 1/1
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 7/10 Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.

Claims

1. A method of treating diabetic nephropathy in a human in need thereof comprising orally administering to the human a vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof, wherein the hyperpermeability-inhibiting amount is from 1 mg to 100 mg per day.

2. The method of claim 1 wherein administration of the danazol or a pharmaceutically acceptable salt thereof, is commenced immediately upon diagnosis of the diabetic nephropathy.

3. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount is from 10 mg to 90 mg of danazol or a pharmaceutically acceptable salt thereof per day.

4. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof is administered to the human at the appearance of one or more early signs of, or a predisposition to develop, diabetic nephropathy.

5. The method of claim 4 wherein administration of danazol or a pharmaceutically acceptable salt thereof is commenced upon the appearance of hyperfiltration.

6. The method of claim 4 wherein administration of danazol or a pharmaceutically acceptable salt thereof is commenced upon the appearance of microalbuminuria.